JNH — Jack Nathan Medical Income Statement
0.000.00%
- CA$0.44m
- CA$13.94m
- CA$19.14m
Annual income statement for Jack Nathan Medical, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2020 January 31st | 2021 January 31st | C2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.62 | 3.85 | 9.64 | 15.5 | 19.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3.46 | 13.9 | 17.7 | 22.3 | 25.5 |
Operating Profit | 0.153 | -10 | -8.03 | -6.8 | -6.35 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.38 | -10.3 | -8.23 | -6.99 | -7.44 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.36 | -9.91 | -8.02 | -6.9 | -6.64 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.36 | -9.9 | -7.81 | -6.9 | -6.64 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.36 | -9.9 | -7.81 | -6.9 | -6.64 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.018 | -0.082 | -0.086 | -0.07 | -0.07 |
Dividends per Share |